| Drug General Information |
| Drug ID |
D00BUO
|
| Former ID |
DIB011788
|
| Drug Name |
MM-141
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 2 |
[1]
|
|---|
| Target and Pathway |
| Target(s) |
Insulin-like growth factor I receptor |
Target Info |
Modulator |
[2]
|
|---|
| Receptor protein-tyrosine kinase erbB-3 |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Ovarian steroidogenesis
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanomahsa04012:ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
TNFalpha Signaling Pathway
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascadeP00012:Cadherin signaling pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junctionerbb2erbb3pathway:ErbB2/ErbB3 signaling events
|
|
ErbB receptor signaling network
|
|
a6b1 and a6b4 Integrin signaling
|
|
Reactome
|
IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1R
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophyWP673:ErbB Signaling Pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Heart Development
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02399137) A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer. U.S. National Institutes of Health. |
|---|
| REF 2 | MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. |
|---|
